Astellas Teams Up With Cytokinetics To Develop Skeletal Muscle Activator
This article was originally published in PharmAsia News
Astellas Pharmaceuticals entered into an agreement regarding the research, development, and commercialization of a skeletal muscle activator with U.S. firm Cytokinetics.
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.